The Impact of Microsatellite Instability and CD8+ Tumor Infiltrating Lymphocytes on Neoadjuvant Chemotherapy Response in Colorectal Cancer: A Prospective Observational Study Authors: Prapanca Nugraha, Yunia Sribudiani, Reno Rudiman, Susanti Susanti, Hermin Aminah Usman, Afrida Helen, Etis Primastari, Bambang Am Am Setya Sulthana, Raden Yohana Azhar, Kiki Lukman Published: 2026 ABSTRACT BackgroundTreatment of colorectal cancer includes surgery and chemotherapy, along with advances in personalised therapies, which focus on achieving safer and more effective outcomes. One of the processes underlying colorectal cancer is microsatellite instability (MSI), and CD8+ Tumor Infiltrating Lymphocytes (TILs) belong to the immune cell subset that shows high impact on cancerous cells. The purpose of this study is to determine whether MSI, CD8+ TILs expression, and chemotherapy response are related.MethodsThis is a retrospective cohort study of colorectal cancer patients who received chemotherapy in the neoadjuvant setting, prior to tumor resection, at a tertiary general hospital in West Java, Indonesia. The MSI examination was carried out using qPCR-HRM (BioColoMelt-Dx), and the TILs CD8+ expression was carried out using immunohistochemistry. The chemotherapy response was evaluated using response evaluation criteria for solid tumors (RECIST).ResultsForty-one subjects were enrolled in this study. There were three subjects (7.3%) with microsatellite instability (1 MSI-L, 2 MSI-H) and 19 subjects (46.3%) with high CD8+ TILs expression. There were 28 (68.3%) subjects in stage III, followed by stage IV (22%) and stage II (9.8%). There were 10 subjects (24%) who showed progressive disease, and 16 subjects (39%) with high expression of CD8+ TILs showed partial chemotherapy response. MSI showed a significant association with age (P<0.05). The CD8+ TILs expression showed no significant association with sex, subtype, grade, or tumor location, but significantly associated with age, stage and chemotherapy response (P < 0.05). Subjects with MSI tend to have early onset disease. Colorectal cancer with high CD8+ TILs expression was less likely to have metastasis (stage IV) and had a better chemotherapy response when compared to those with low CD8+ TILs expression.ConclusionThe MSI status showed no significant relationship with CD8+ TILs. Patients with high CD8+ TILs showing a relationship with a better chemotherapy response and a better prognosis in colorectal cancer patients. Introduction Colorectal cancer is one of the leading causes of death worldwide, ranking third globally and showing the highest prevalence in developed countries. The number of cases continues to rise annually, with approximately 1.9 million new diagnoses and 0.9 million deaths recorded in 2022.1–3 According to GLOBOCAN 2022 data, colorectal cancer is the fourth most common cancer in Indonesia, with 35,676 new cases and an incidence rate of 16.5 per 100,000 males and 8.6 per 100,000 females.1 These increasing numbers are thought to be associated with lifestyle changes, particularly the adoption of a more “westernized” lifestyle. Although many reports highlight growing awareness of colorectal cancer, some studies also indicate declining incidence and mortality rates. Improved understanding of the disease has contributed to reduced incidence, with a reported 29% decrease in all cancer types, including colorectal cancer.4,5 Furthermore, one study reported a 53% reduction in colorectal cancer mortality in the United States from 1975 to 2014. This decline is supported by increased utilization of screening methods, allowing earlier detection and treatment, along with advancements in therapeutic modalities and continuously updated medical knowledge.6,7 The progression of colorectal cancer from normal cells begins with an accumulation of genetic mutations, which may occur over a period of 10 to 15 years, although this duration can vary. One source of these mutations is chromosomal instability. Microsatellites: short, repetitive DNA sequences scattered throughout the genome are particularly susceptible to errors during replication, which can lead to frameshift mutations and subsequent protein inactivation. These alterations are normally detected by the mismatch repair (MMR) system, which identifies and corrects DNA damage, including replication errors. However, when mutations occur in genes encoding components of the MMR system, defective repair ensues, allowing genetic mutations to accumulate.8,9 Today, biomarkers have become clinically significant tools used to predict tumor progression and prognosis. Microsatellite instability (MSI) has been shown in several studies to be associated with tumor-infiltrating lymphocytes (TILs). Research by Schrammen et al, Brummel et al, and Thomas et al demonstrated that MSI is most predictive in TILs-rich tumor regions. Specifically, MSI-H tumors exhibit increased intraepithelial CD8⁺ T-cell infiltration compared with microsatellite-stable (MSS) or microsatellite-low (MSI-L) cancers.10–12 MSI results from defective DNA mismatch repair and is considered a biomarker associated with less aggressive tumor behavior. MSI tumors tend to have high levels of TILs due to the formation of neoantigens, which arise from frameshift mutations in coding regions caused by MMR gene inactivation (dMMR). These neoantigens stimulate immune cell infiltration, enabling immune surveillance, limiting metastatic potential, and contributing to better clinical outcomes, particularly in early-stage colon cancer. MSI status is also important for guiding treatment decisions, especially in stage II colon cancer, where adjuvant chemotherapy is often considered a secondary therapeutic option. Patients with MSI-H or dMMR tumors generally have better prognoses and derive less benefit from adjuvant chemotherapy compared with those with stage II MSS tumors.8,10,12 High immune cell infiltration is associated with a favorable prognosis, as demonstrated in several studies.12 Cytotoxic CD8⁺ T cells, which recognize antigens presented on target cells via T-cell receptors, eliminate malignant cells through the exocytosis of cytotoxic granules containing perforin and granzymes.13 According to Huh et al, patients with high levels of TILs exhibited improved survival compared with those with low TILs levels, confirming that TILs serve as a significant prognostic factor.14 In the early stages, colon cancer is managed surgically through either local or wide excision, with or without anastomosis. Patients with high-risk stage II disease are often recommended adjuvant chemotherapy. Fluorouracil (5-FU) with leucovorin and oxaliplatin-based regimens remain the standard options for adjuvant therapy. Tumor resection may also be performed in selected cases of stage IV disease. In more advanced stages, treatment commonly involves staged resection or resection of synchronous metastatic lesions. A meta-analysis demonstrated that the addition of adjuvant 5-FU chemotherapy significantly improves overall survival compared with surgery alone.15–17 According to several studies, MSI is associated with higher expression of CD8⁺ TILs in the tumor microenvironment, a relationship driven by the accumulation of mutations that lead to neoantigen formation. Increased CD8⁺ TILs are also linked to elevated expression of specific immune checkpoints. Thus, identifying MSI status and CD8⁺ TILs in patients with colorectal cancer (CRC) can aid in tailoring individualized treatment based on tumor characteristics, underlying mutations, and expected prognosis. Therefore, data regarding the relationship between MSI, CD8⁺ TILs, and chemotherapy response are needed. This study aims to evaluate the association between MSI and CD8⁺ TILs with chemotherapy response. Methods Study Design and Setting This research employed a retrospective observational design and adhered to the Strengthening the Reporting of Observational Epidemiological Studies (STROBE) guidelines.18,19 The study was conducted at Hasan Sadikin General Hospital in West Java, Indonesia. The subjects were colorectal cancer patients who presented to the digestive surgery department between July 2024 and June 2025. Patients who had completed chemotherapy were randomly selected for inclusion. The inclusion criteria were: (1) complete medical records, including pathological examination data; (2) age ≥18 years; (3) completion of chemotherapy at the same hospital; and (4) consent to participate as research subjects. Because objective chemotherapy response can only be validly assessed in the presence of measurable disease, the inclusion criteria were further restricted to patients who had not undergone surgical tumor resection prior to chemotherapy and who received chemotherapy in the neoadjuvant setting. Exclusion criteria included stage I disease, a history of other malignancies, discontinuation of chemotherapy, loss to follow-up, prior curative-intent tumor resection before chemotherapy, and rectal cancer cases treated with radiation therapy. This study was conducted in accordance with the Declaration of Helsinki, and the study proposal, protocol, research participant recruitment materials, participant information sheet, and informed consent form were submitted to the Hasan Sadikin General Hospital’s institutional ethics committee, from which ethical approval and research permission were obtained prior to data collection (approval number: LB.02.01/X.6.5/8/2024). All research participants were provided with detailed information about the study, and written informed consent was obtained from each participant or from a legal guardian when applicable. DNA Isolation and Microsatellite Instability Examination The procedures for DNA isolation and microsatellite instability examination were carried out at the University Genetic and Biomolecular Laboratory using standard, approved protocols with the BioColoMelt-Dx kit (Biofarma). The DNA used for microsatellite instability analysis was obtained either from stored biological material (BBT) or isolated from fresh tissue collected during biopsy or surgery. Fresh tissue samples were preserved in RNAlater® (Qiagen) solution, and DNA was subsequently extracted using the Quick-DNA Isolation Kit (Zymo Research) following the manufacturer’s protocol. The concentration and purity of the isolated DNA were assessed using a NanoDrop 2000™ spectrophotometer (Thermo Fisher Scientific), with purity determined by the OD 230/260 and 280/260 ratios. Microsatellite instability analysis was performed using the BioColoMelt-Dx real-time (q) PCR-HRM Kit (Pathgen). Target loci were amplified using the qPCR-HRM method with 1000 ng of extracted DNA, which was diluted with nuclease-free water (NFW) to a final concentration of 20 ng/µL. The reaction mixture was prepared by combining 8 µL of the master mix for each marker with 2 µL of the DNA template. The high-resolution melting (HRM) qPCR procedure consisted of three main stages. Denaturation was performed at 95 °C for 10 seconds, followed by annealing at 55 °C for 30 seconds, and DNA strand elongation at 72 °C for 20 seconds. A final extension step was carried out at 72 °C for 2 minutes. This was followed by a two-step pre-melting process: first at 95 °C for 15 seconds and then at 60 °C for 5 seconds. HRM analysis was performed from 60 °C to 90 °C with a temperature increment of 0.3 °C per cycle using the mononucleotide microsatellite markers BAT-25, BAT-26, MONO-27, NR-21, and NR-24. Interpretation of results followed the manufacturer’s instructions provided in the kit. Samples showing mutant amplification displayed melting curve patterns that differed from those of wild-type samples, as shown in Figure 1. Microsatellite status is expressed as microsatellite stable (MSS), microsatellite instability-low (MSI-L), and microsatellite instability-high (MSI-H). Figure 1Microsatellite instability (MSI) analysis of Sample no. 1 and Sample no. 2 using five markers (MSI-1 to MSI-5). (A) MSI-1: Sample no. 1 unstable, Sample no. 2 stable. (B) MSI-2: Sample no. 1 unstable, Sample no. 2 stable. (C) MSI-3: Sample no. 1 stable, Sample no. 2 stable. (D) MSI-4: Sample no. 1 stable, Sample no. 2 stable. (E) MSI-5: Sample no. 1 unstable, Sample no. 2 stable. Based on instability at three of five loci (A, B, and E), Sample no. 1 was classified as MSI-High, whereas Sample no. 2, stable at all five loci, was classified as MSS.Five graphs analyze microsatellite instability (MSI) for markers MSI-1 to MSI-5, comparing Control, Sample 1 and Sample 2. Axis labels and units are missing. Image A (MSI-1): Control shows a mid-range trough, Sample 1 a shallower trough, Sample 2 a deeper trough at higher x values. Sample 1 is Positive (Heteroduplex), Sample 2 is Negative. Image B (MSI-2): Control at lower x values, Sample 1 at mid, Sample 2 at higher. Sample 1 is Positive, Sample 2 is Negative. Image C (MSI-3): Control has a pronounced V shape, samples show milder curves. Both samples are Negative. Image D (MSI-4): Sample 2 has the deepest trough at higher x values, Sample 1 at mid, Control at lower to mid. Both samples are Negative. Image E (MSI-5): Control dips at mid x values, Sample 1 at lower, Sample 2 at mid. Sample 1 is Positive, Sample 2 is Negative. Overall, Sample 1 is Positive for MSI-1, 2 and 5, Negative for 3 and 4. Sample 2 is Negative for all markers.Graphs of MSI analysis for markers MSI-1 to MSI-5 comparing Control and two samples. Microsatellite instability (MSI) analysis of Sample no. 1 and Sample no. 2 using five markers (MSI-1 to MSI-5). (A) MSI-1: Sample no. 1 unstable, Sample no. 2 stable. (B) MSI-2: Sample no. 1 unstable, Sample no. 2 stable. (C) MSI-3: Sample no. 1 stable, Sample no. 2 stable. (D) MSI-4: Sample no. 1 stable, Sample no. 2 stable. (E) MSI-5: Sample no. 1 unstable, Sample no. 2 stable. Based on instability at three of five loci (A, B, and E), Sample no. 1 was classified as MSI-High, whereas Sample no. 2, stable at all five loci, was classified as MSS. Immunohistochemical Analysis of CD8⁺ Tumor-Infiltrating Lymphocytes The immunohistochemical analysis of CD8⁺ tumor-infiltrating lymphocytes was performed at the hospital’s Anatomical Pathology Laboratory using standard, approved protocols with the anti-CD8α antibody (Abcam). The labeled streptavidin–biotin immunoperoxidase complex technique was used to stain TILs CD8⁺ expression, followed by counterstaining with hematoxylin and eosin (H&E). Tissue sections were first immersed in ethanol to undergo deparaffinization and rehydration. Evaluation of CD8⁺ T-cell expression was performed semi-quantitatively. Positive CD8⁺ T-cell staining was identified by brown coloration on the cell membrane and within portions of the cytoplasm. Liver tissue served as a positive control for CD8⁺ immunostaining. Immunohistochemical staining for CD8⁺ was considered positive when lymphocytes demonstrated clear membranous immunoreactivity.20,21 Two pathologists independently examined the specimens. Tumor-infiltrating lymphocytes (TILs) were classified into two categories: high and low expression, as shown in Figure 2. Figure 2TILs CD8+ expression evaluation using immunohistochemistry: (A) Normal or low TIL CD8+ expression (0–75%); (B) High TILs CD8+ expression (>75%), indicated by arrows.Two micrographs of stained tissue: A with blue nuclei, B with brown staining marked by a black arrow. TILs CD8+ expression evaluation using immunohistochemistry: (A) Normal or low TIL CD8+ expression (0–75%); (B) High TILs CD8+ expression (>75%), indicated by arrows. Chemotherapy Response Evaluation Using RECIST Chemotherapy response was assessed using the Response Evaluation Criteria in Solid Tumors (RECIST). Tumor response was evaluated based on anatomical measurements, using the longest tumor diameter obtained from pre- and post-chemotherapy abdominal computed tomography (CT) scans. A complete response (CR) was defined as the disappearance of all target lesions; a partial response (PR) was defined as a reduction in tumor size of >30%; progressive disease (PD) was defined as an increase in tumor size of >20%; and stable disease (SD) was defined as the absence of CR, PR, nor PD.22,23 Data Analysis The collected data were processed and analyzed using SPSS version 26 (SPSS Inc., Chicago, IL, USA). Numerical data are presented as the mean ± standard deviation, while categorical data are expressed as percentages. The chi-square test or Fisher’s exact test (as appropriate, based on expected cell counts) was used to evaluate the relationships among MSI status, CD8⁺ TILs expression, and chemotherapy response. A p-value of <0.05 was considered statistically significant. Results Subject Characteristics There were 41 research subjects, and their characteristics are presented in Table 1. Of these, 24 were female and 17 were male. The mean age was 55.1 ± 12.6 years (range 22–79 years), with 29 patients (70.7%) older than 50 years. Histologically, most patients had adenocarcinoma (92.7%), and 78% had well-differentiated tumors. Molecular analysis showed that the majority of patients, 38 cases (92.7%), had microsatellite-stable (MSS) status, while only a small proportion were classified as MSI-L (2.4%) or MSI-H (4.9%). Thirty patients (73.2%) had rectal cancer, while 11 (26.8%) had colon cancer. High CD8⁺ TIL expression was observed in 19 patients (46.3%). The most common chemotherapy responses were partial response in 17 patients (41.5%) and stable disease in 13 patients (31.7%).Table 1Characteristics of Research SubjectsVariableProportion (%)AgeMean55.1 ± 12.6 yearsMin - Max22 - 79 yearsAge< 5012 (29.3%)≥ 5029 (70.7%)SexMale17 (41.5%)Female24 (58.5%)HistologicAdenocarcinoma38 (92.7%)Signet Ring Cell2 (4.9%)Mucinous Adenocarcinoma1 (2.4%)GradeWell diff32 (78%)Moderately diff4 (9.8%)Poorly diff2 (4.9%)Specific3 (7.3%)Tumor LocationColon11 (26.8%)Rectum30 (73.2%)StageII4 (9.8%)III28 (68.3%)IV9 (22%)MetastasesLiver8 (19.5%)Lung1 (2.4%)MSIMSS38 (92.7%)MSI-L1 (2.4%)MSI-H2 (4.9%)CD8+ TILsLow expression22 (53.7%)High expression19 (46.3%)Chemotherapy RegimenFluorouracil and leucovorin21 (51.2%)Fluorouracil, leucovorin and oxaliplatin20 (48.8%)Chemotherapy ResponseComplete response1 (2.4%)Partial response17 (41.5%)Stable disease13 (31.7%)Progressive disease10 (24%) Table 1Characteristics of Research SubjectsVariableProportion (%)AgeMean55.1 ± 12.6 yearsMin - Max22 - 79 yearsAge< 5012 (29.3%)≥ 5029 (70.7%)SexMale17 (41.5%)Female24 (58.5%)HistologicAdenocarcinoma38 (92.7%)Signet Ring Cell2 (4.9%)Mucinous Adenocarcinoma1 (2.4%)GradeWell diff32 (78%)Moderately diff4 (9.8%)Poorly diff2 (4.9%)Specific3 (7.3%)Tumor LocationColon11 (26.8%)Rectum30 (73.2%)StageII4 (9.8%)III28 (68.3%)IV9 (22%)MetastasesLiver8 (19.5%)Lung1 (2.4%)MSIMSS38 (92.7%)MSI-L1 (2.4%)MSI-H2 (4.9%)CD8+ TILsLow expression22 (53.7%)High expression19 (46.3%)Chemotherapy RegimenFluorouracil and leucovorin21 (51.2%)Fluorouracil, leucovorin and oxaliplatin20 (48.8%)Chemotherapy ResponseComplete response1 (2.4%)Partial response17 (41.5%)Stable disease13 (31.7%)Progressive disease10 (24%) Characteristics of Research Subjects Univariate Analysis of Subject Characteristics in Relation to MSI Status One variable, age showed a statistically significant relationship (p < 0.05) with MSI status in the univariate analysis, as shown in Table 2. Among subjects with MSI status, all individuals fell into the early-onset category (3/3; 100%). In contrast, most subjects with MSS status were classified as late-onset.Table 2Univariate Analysis of Subject Characteristics in Relation to MSI StatusMSSMSI-LMSI-HP value*Age0.021Early onset (<50)9 (22%)1 (2.4%)2 (4.9%)Late onset (>50)29 (70.7%)00Sex0.999Male16 (39%)01 (2.4%)Female22 (53.7%)1 (2.4%)1 (2.4%)Histologic type0.999Adenocarcinoma25 (61%)1 (2.4%)2 (4.9%)Mucinous Adenocarcinoma1 (2.4%)00Signet ring cell2 (4.9%)00Grade0.999Well differentiated29 (70.7%)1 (2.4%)2 (4.9%)Moderately differentiated4 (9.8%)00Poorly differentiated2 (4.9%)00Specific3 (7.3%)00Tumor location0.067Colon9 (22%)02 (4.9%)Rectum29 (70.7%)1 (2.4%)0Stage0.279II4 (9.8%)00III27 (65.9%)01 (2.4%)IV7 (17%)1 (2.4%)1 (2.4%)CD8+ TILs expressionLow expression20 (48.8%)1 (2.4%)1 (2.4%)0.999High expression18 (43.9%)01 (2.4%)Chemotherapy regimen0.737Fluorouracil and leucovorin20 (48.8%)01 (2.4%)Fluorouracil, leucovorin and oxaliplatin.18 (43.9%)1 (2.4%)1 (2.4%)Chemotherapy response0.346Complete response1 (2.4%)00Partial response16 (39%)01 (2.4%)Stable disease13 (31.7%)00Progressive disease8 (19.5%)1 (2.4%)1 (2.4%)Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Table 2Univariate Analysis of Subject Characteristics in Relation to MSI StatusMSSMSI-LMSI-HP value*Age0.021Early onset (<50)9 (22%)1 (2.4%)2 (4.9%)Late onset (>50)29 (70.7%)00Sex0.999Male16 (39%)01 (2.4%)Female22 (53.7%)1 (2.4%)1 (2.4%)Histologic type0.999Adenocarcinoma25 (61%)1 (2.4%)2 (4.9%)Mucinous Adenocarcinoma1 (2.4%)00Signet ring cell2 (4.9%)00Grade0.999Well differentiated29 (70.7%)1 (2.4%)2 (4.9%)Moderately differentiated4 (9.8%)00Poorly differentiated2 (4.9%)00Specific3 (7.3%)00Tumor location0.067Colon9 (22%)02 (4.9%)Rectum29 (70.7%)1 (2.4%)0Stage0.279II4 (9.8%)00III27 (65.9%)01 (2.4%)IV7 (17%)1 (2.4%)1 (2.4%)CD8+ TILs expressionLow expression20 (48.8%)1 (2.4%)1 (2.4%)0.999High expression18 (43.9%)01 (2.4%)Chemotherapy regimen0.737Fluorouracil and leucovorin20 (48.8%)01 (2.4%)Fluorouracil, leucovorin and oxaliplatin.18 (43.9%)1 (2.4%)1 (2.4%)Chemotherapy response0.346Complete response1 (2.4%)00Partial response16 (39%)01 (2.4%)Stable disease13 (31.7%)00Progressive disease8 (19.5%)1 (2.4%)1 (2.4%)Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Univariate Analysis of Subject Characteristics in Relation to MSI Status Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Univariate Analysis of Variables in Relation to CD8⁺ TILs Expression Three variables demonstrated a statistically significant association (p < 0.05) with CD8⁺ TILs expression in the univariate analysis, as shown in Table 3. In stage III disease, 16 subjects (39%) exhibited high CD8⁺ TILs expression, which was higher than that observed in stage IV disease. Patients with high CD8⁺ TILs expression were more frequently observed in the partial response group than in the progressive disease group, whereas the opposite pattern was observed among patients with low CD8⁺ TILs expression.Table 3Univariate Analysis of Subject Characteristics in Relation to CD8⁺ TILs ExpressionLow ExpressionHigh ExpressionP value*Age0.014aEarly onset (<50)10 (24%)2 (4.9%)Late onset (≥50)12 (29.3%)17 (41.5%)Sex0.577aMale10 (24%)7 (17%)Female12 (29.3%)12 (29.3%)Histologic type0.999bAdenocarcinoma20 (48.8%)18 (43.9%)Mucinous Adenocarcinoma1 (2.4%)0Signet ring cell1 (2.4%)1 (2.4%)Grade0.217bWell differentiated15 (36.6%)17 (41.5%)Moderately differentiated4 (9.8%)0Poorly differentiated1 (2.4%)1 (2.4%)Specific2 (4.9%)1 (2.4%)Tumor location0.945aColon6 (14.6%)5 (12.2%)Rectum16 (39%)14 (34.1%)Stage0.044bII2 (4.9%)2 (4.9%)III12 (29.3%)16 (39%)IV8 (19.5%)1 (2.4%)Chemotherapy regimen0.427aFluorouracil and leucovorin10 (24%)11 (26.8%)Fluorouracil, leucovorin and oxaliplatin.12 (29.3%)8 (19.5%)Chemotherapy response0.001bComplete response1 (2.4%)0Partial response1 (2.4%)16 (39%)Stable disease10 (24%)3 (7.3%)Progressive disease10 (24%)0Notes: *asuperscript = chi square test, b superscript = fisher exact test, CI95%, bold values indicate a statistically significant association (P <0.05). Table 3Univariate Analysis of Subject Characteristics in Relation to CD8⁺ TILs ExpressionLow ExpressionHigh ExpressionP value*Age0.014aEarly onset (<50)10 (24%)2 (4.9%)Late onset (≥50)12 (29.3%)17 (41.5%)Sex0.577aMale10 (24%)7 (17%)Female12 (29.3%)12 (29.3%)Histologic type0.999bAdenocarcinoma20 (48.8%)18 (43.9%)Mucinous Adenocarcinoma1 (2.4%)0Signet ring cell1 (2.4%)1 (2.4%)Grade0.217bWell differentiated15 (36.6%)17 (41.5%)Moderately differentiated4 (9.8%)0Poorly differentiated1 (2.4%)1 (2.4%)Specific2 (4.9%)1 (2.4%)Tumor location0.945aColon6 (14.6%)5 (12.2%)Rectum16 (39%)14 (34.1%)Stage0.044bII2 (4.9%)2 (4.9%)III12 (29.3%)16 (39%)IV8 (19.5%)1 (2.4%)Chemotherapy regimen0.427aFluorouracil and leucovorin10 (24%)11 (26.8%)Fluorouracil, leucovorin and oxaliplatin.12 (29.3%)8 (19.5%)Chemotherapy response0.001bComplete response1 (2.4%)0Partial response1 (2.4%)16 (39%)Stable disease10 (24%)3 (7.3%)Progressive disease10 (24%)0Notes: *asuperscript = chi square test, b superscript = fisher exact test, CI95%, bold values indicate a statistically significant association (P <0.05). Univariate Analysis of Subject Characteristics in Relation to CD8⁺ TILs Expression Notes: *asuperscript = chi square test, b superscript = fisher exact test, CI95%, bold values indicate a statistically significant association (P <0.05). Univariate Analysis of Subject Characteristics in Relation to Chemotherapy Response Univariate analysis of subject characteristics in relation to chemotherapy response is presented in Table 4. Four variables demonstrated a statistically significant association with chemotherapy response: age (p = 0.009), disease stage (p = 0.001), chemotherapy regimen (p = 0.006), and combined MSI status with CD8⁺ TILs expression (p = 0.001). Progressive disease was more common among early-onset patients (7 subjects, 17%) than late-onset patients (3 subjects, 7.3%), whereas late-onset patients more frequently achieved a partial response (15 subjects, 36.6%). By disease stage, no stage II or stage III patients achieved a complete response, and progressive disease was concentrated in stage IV (7 subjects, 17%), while stage III patients most frequently achieved a partial response (14 subjects, 34.1%). Regarding chemotherapy regimen, progressive disease was more frequent among patients who received fluorouracil, leucovorin, and oxaliplatin (9 subjects, 22%) than among those who received fluorouracil and leucovorin alone (1 subject, 2.4%), while the latter group more often achieved a partial response (12 subjects, 29.3%). The distribution of chemotherapy response according to combined MSI status and CD8⁺ TILs expression also demonstrated a statistically significant association (p = 0.001). Patients with MSS and low CD8⁺ TILs expression most frequently exhibited stable disease (24%) and progressive disease (19.5%), with fewer achieving complete or partial responses. In contrast, patients with MSS and high CD8⁺ TILs expression predominantly showed a partial response (36.6%), and no cases of progressive disease were observed in this group. The single patients with MSI-L and MSI-H status combined with low CD8⁺ TILs expression each experienced progressive disease (2.4% each), whereas the single patient with MSI-H and high CD8⁺ TILs expression achieved a partial response (2.4%), indicating that higher CD8⁺ TILs expression is associated with a more favorable chemotherapy response. No significant associations were observed between chemotherapy response and sex, histologic type, tumor location, or tumor grade (p > 0.05 for all).Table 4Univariate Analysis Subject Characteristics in Relation to Chemotherapy ResponseVariablesCompletePartialStableProgressiveP values*Age Early onset (<50)0 (0.0%)2 (4.9%)3 (7.3%)7 (17%)0.009Late onset (≥50)1 (2.4%)15 (36.6%)10 (24%)3 (7.3%) Sex Male1 (2.4%)7 (17%)6 (14.6%)3 (7.3%)0.652Female0 (0.0%)10 (24%)7 (17%)7 (17%) Histologic type Adenocarcinoma1 (2.4%)16 (39%)13 (31.7%)8 (19.5%)0.346Mucinous Adenocarcinoma0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)Signet ring cell0 (0.0%)1 (2.4%)0 (0.0%)1 (2.4%) Tumor location Colon1 (2.4%)6 (14.6%)2 (4.9%)2 (4.9%)0.266Rectum0 (0.0%)11 (36.7%)11 (36.7%)8 (19.5%) Grade Well differentiated1 (2.4%)16 (39%)10 (24%)5 (12.2%)0.138Moderately differentiated0 (0.0%)0 (0.0%)2 (4.9%)2 (4.9%)Poorly differentiated0 (0.0%)0 (0.0%)1 (2.4%)1 (2.4%)Specific0 (0.0%)1 (2.4%)0 (0.0%)2 (4.9%) Stage II0 (0.0%)2 (4.9%)2 (4.9%)0 (0.0%)0.001III0 (0.0%)14 (34.1)11 (36.7%)3 (7.3%)IV1 (2.4%)1 (2.4%)0 (0.0%)7 (17%) Chemotherapy regimen Fluorouracil and leucovorin0 (0.0%)12 (29.3%)8 (19.5%)1 (2.4%)0.006Fluorouracil, leucovorin and oxaliplatin.1 (2.4%)5 (12.2%)5 (12.2%)9 (22%) MSI + TILs MSS Low CD8+1 (2.4%)1 (2.4%)10 (24%)8 (19.5%)0.001MSS High CD8+0 (0.0%)15 (36.6%)3 (7.3%)0 (0.0%)MSI-L Low CD8+0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)MSI-H Low CD8+0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)MSI-H High CD8+0 (0.0%)1 (2.4%)0 (0.0%)0 (0.0%) Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Table 4Univariate Analysis Subject Characteristics in Relation to Chemotherapy ResponseVariablesCompletePartialStableProgressiveP values*Age Early onset (<50)0 (0.0%)2 (4.9%)3 (7.3%)7 (17%)0.009Late onset (≥50)1 (2.4%)15 (36.6%)10 (24%)3 (7.3%) Sex Male1 (2.4%)7 (17%)6 (14.6%)3 (7.3%)0.652Female0 (0.0%)10 (24%)7 (17%)7 (17%) Histologic type Adenocarcinoma1 (2.4%)16 (39%)13 (31.7%)8 (19.5%)0.346Mucinous Adenocarcinoma0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)Signet ring cell0 (0.0%)1 (2.4%)0 (0.0%)1 (2.4%) Tumor location Colon1 (2.4%)6 (14.6%)2 (4.9%)2 (4.9%)0.266Rectum0 (0.0%)11 (36.7%)11 (36.7%)8 (19.5%) Grade Well differentiated1 (2.4%)16 (39%)10 (24%)5 (12.2%)0.138Moderately differentiated0 (0.0%)0 (0.0%)2 (4.9%)2 (4.9%)Poorly differentiated0 (0.0%)0 (0.0%)1 (2.4%)1 (2.4%)Specific0 (0.0%)1 (2.4%)0 (0.0%)2 (4.9%) Stage II0 (0.0%)2 (4.9%)2 (4.9%)0 (0.0%)0.001III0 (0.0%)14 (34.1)11 (36.7%)3 (7.3%)IV1 (2.4%)1 (2.4%)0 (0.0%)7 (17%) Chemotherapy regimen Fluorouracil and leucovorin0 (0.0%)12 (29.3%)8 (19.5%)1 (2.4%)0.006Fluorouracil, leucovorin and oxaliplatin.1 (2.4%)5 (12.2%)5 (12.2%)9 (22%) MSI + TILs MSS Low CD8+1 (2.4%)1 (2.4%)10 (24%)8 (19.5%)0.001MSS High CD8+0 (0.0%)15 (36.6%)3 (7.3%)0 (0.0%)MSI-L Low CD8+0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)MSI-H Low CD8+0 (0.0%)0 (0.0%)0 (0.0%)1 (2.4%)MSI-H High CD8+0 (0.0%)1 (2.4%)0 (0.0%)0 (0.0%) Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Univariate Analysis Subject Characteristics in Relation to Chemotherapy Response Notes: *Fisher exact test analysis, CI 95%, bold values indicate a statistically significant association (P <0.05). Discussion The age distribution of our cohort, with a mean of 55.1 years, reinforces the well-established observation that colorectal cancer predominantly affects individuals over 50 years of age, reflecting cumulative genetic and environmental risk exposure with aging. The slightly higher proportion of female patients contrasts with the commonly reported male predominance but may be explained by the postmenopausal decline in the protective effects of estrogen. The overwhelming predominance of adenocarcinoma and well-differentiated tumors in this study is consistent with the typical histopathological profile of colorectal cancer and suggests that most tumors retained a relatively favorable degree of differentiation. The predominance of rectal over colonic tumors aligns with reports that distal colorectal cancer remains the most common anatomical presentation.24–26 Importantly, the high proportion of patients diagnosed at stage III and IV underscores the persistent challenge of late-stage presentation in clinical practice, with liver metastasis emerging as the dominant site of distant spread, highlighting the aggressive nature and advanced burden of disease at diagnosis in our setting as shown in Table 1. Microsatellite instability analysis in this study identified MSI in 7.3% of subjects (2.4% MSI-L, 4.9% MSI-H), while the majority of patients (92.7%) exhibited microsatellite stability (MSS). No significant associations were observed between MSI status and sex, histopathological subtype, tumor grade, or disease stage as shown in Table 2. These findings contrast with previous reports indicating that approximately 15% of colorectal cancers exhibit MSI, with 3% linked to Lynch syndrome and 12% representing sporadic cases.27,28 The relatively low prevalence of MSI in our cohort is consistent with prior Indonesian data but remains lower than that reported in Western populations.29 Although MSI status was not associated with clinicopathological characteristics in this study, its clinical relevance remains substantial, as MSI tumors are known to have distinct therapeutic implications. In particular, MSI status predicts limited benefit from 5-FU–based chemotherapy in early-stage disease but a favorable response to immunotherapy in advanced-stage colorectal cancer, underscoring the importance of routine MSI testing for precision oncology.8 The present study demonstrates that CD8⁺ TILs expression is significantly associated with age, disease stage, and chemotherapy response, but not with sex, histopathological subtype, tumor grade, or tumor location as shown in Table 3. Patients with high CD8⁺ TILs expression were less likely to present with stage IV disease, suggesting a potential protective role of intratumoral immune infiltration against distant metastasis. Moreover, the better chemotherapy response observed in patients with high CD8⁺ TILs expression supports the concept that an active tumor immune microenvironment enhances treatment sensitivity, whereas low CD8⁺ TILs expression was more frequently associated with stable and progressive disease. These findings are consistent with previous studies. Trabelsi et al reported that high CD8⁺ TILs expression in both the central tumor and invasive margin was associated with significantly improved overall survival in colorectal cancer patients.30 Similarly, Xin et al demonstrated that preoperative chemotherapy increases tumor antigen exposure and subsequently enhances CD8⁺ TILs infiltration, and that CD8⁺ TILs serve as an independent prognostic factor, particularly in stage IV colorectal cancer.31 Although no association between CD8⁺ TILs expression and most clinicopathological factors was observed in the present study, the consistent survival benefit reported in other studies highlights the important prognostic and predictive role of CD8⁺ TILs in colorectal cancer. In the present study, univariate analysis showed no significant association between MSI status and CD8⁺ TILs expression (p = 0.999). Cross-tabulation revealed that most patients with high CD8⁺ TILs expression had MSS tumors, while only a small proportion had MSI tumors. Response to therapy differed significantly according to microsatellite status and CD8+ TILs expression (p = 0.001), with high CD8+ TILs expression, particularly in MSS tumors associated with better response rates, while low CD8+ TILs expression was associated with poorer outcomes as shown in Table 4. These findings suggest that, in this cohort, CD8⁺ TILs infiltration was not strongly driven by MSI status. This result contrasts with several previous studies that have demonstrated a close relationship between MSI status and increased immune cell infiltration. In a study by Millen et al, MSI tumors exhibited significantly higher CD8⁺ TILs density than MSS tumors, although CD8⁺ TILs expression did not significantly affect overall survival.32 Similarly, Toh et al reported significantly higher levels of CD8⁺ tissue-resident memory T cells (Trm) in MSI tumors compared to MSS tumors, highlighting the enhanced immunogenicity of MSI colorectal cancer. However, despite the presence of Trm cells, tumor progression may still occur, emphasizing that immune protection is not absolute.33 Consistent with these findings, Xin et al also demonstrated that MSI tumors were associated with higher CD8⁺ TILs infiltration and improved overall survival in patients with stage IV colorectal cancer.31 Their results further support the concept that MSI tumors represent an immune-infiltrated phenotype that is more responsive to immunotherapy. The lack of a significant association between MSI status and CD8⁺ TIL expression in our study may be influenced by the small proportion of MSI cases. Nevertheless, these findings underscore the biological complexity of tumor–immune interactions and highlight the importance of further studies to better define the immunogenic landscape of MSI and MSS colorectal cancer and its implications for immunotherapeutic strategies. The relatively small sample size and limited study area may have influenced the statistical power and generalizability of the findings. In addition, because the chemotherapy-response analysis in this study was restricted to patients with measurable disease before treatment, patients who had undergone curative-intent tumor resection prior to chemotherapy were excluded; as a result, adjuvant-treatment outcomes such as disease-free survival, recurrence-free survival, and recurrence rate could not be evaluated for this cohort, owing to the limited follow-up duration available in this sample. The short observation period may also not fully reflect the dynamic nature of CD8⁺ TILs activity, as chronic immune checkpoint expression can reduce CD8⁺ TILs function over time. MSI tumors may also develop adaptive immune escape mechanisms that limit recognition by CD8⁺ TILs, which could not be fully assessed in this study. Although CD8⁺ TILs and MSI expression are associated with more favorable chemotherapy responses and improved prognosis, these results should be interpreted cautiously. Larger, multicenter studies with longer follow-up are needed to better evaluate the interactions between MSI status, CD8⁺ TILs expression, and treatment response. Future research should also investigate whether patients with MSS tumors and low CD8⁺ TILs expression might still benefit from immunotherapy, explore immune evasion mechanisms in MSI tumors, and determine the optimal role of personalized immunotherapy based on immune and molecular profiles. Conclusion This study shows that high CD8⁺ TILs expression is significantly associated with earlier disease stage and better chemotherapy response in colorectal cancer, whereas MSI status was uncommon and showed limited clinicopathological associations. Patients with high CD8⁺ TILs expression demonstrated superior treatment outcomes regardless of MSI status, highlighting immune infiltration as a key predictor of chemotherapy response. Although MSI tumors are known to benefit from immunotherapy, their low prevalence in this cohort limited their clinical impact. These findings support the clinical potential of CD8⁺ TILs expression as a practical biomarker for treatment stratification, while larger studies are needed for further validation.